Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study.

Cetiner S

BMC endocrine disorders14 Mar 2026Cited by 1 (Europe PMC)

PMID41832437PMCIDPMC13020155DOI10.1186/s12902-026-02232-yPepBankPUB-41832437

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study15

13 results from studies that gave the peptide. 13 results from people.

01HumanObservational studyEfficacy outcome
In adults with newly diagnosed type 2 diabetes, semaglutide was associated with greater weight reduction than dulaglutide after adjustment.
In plain wordsIn adults with new type 2 diabetes, semaglutide was linked to more weight loss than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseWeight reduction versus dulaglutide
Study
n = 106
Comparator
Dulaglutide 1.5 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
After adjustment for baseline covariates, semaglutide was associated with greater weight reduction and LDL cholesterol improvement
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243705
02HumanObservational studyEfficacy outcome
In adults with newly diagnosed type 2 diabetes, semaglutide was associated with greater LDL cholesterol improvement than dulaglutide after adjustment.
In plain wordsIn adults with new type 2 diabetes, semaglutide was linked to a bigger LDL cholesterol drop than dulaglutide.
Peptide
Semaglutide
Outcome
DecreaseLDL cholesterol improvement versus dulaglutide
Study
n = 106
Comparator
Dulaglutide 1.5 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
After adjustment for baseline covariates, semaglutide was associated with greater weight reduction and LDL cholesterol improvement
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243706
03HumanObservational studyEfficacy outcome
In adults with newly diagnosed type 2 diabetes, HbA1c reduction with semaglutide was comparable to dulaglutide.
In plain wordsIn adults with new type 2 diabetes, long-term blood sugar fell about the same with semaglutide and dulaglutide.
Peptide
Semaglutide
Outcome
No significant changeHbA1c reduction versus dulaglutide
Study
n = 106
Comparator
Dulaglutide 1.5 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
whereas HbA1c reduction was comparable between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243707
04HumanObservational studyEfficacy outcome
In adults with newly diagnosed diabetes receiving a hypocaloric diet, dulaglutide was linked to less adjusted weight reduction than semaglutide.
In plain wordsIn adults with new diabetes receiving dietary care, dulaglutide was linked to less weight loss than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight reduction
Study
n = 106
Comparator
Semaglutide 1.0 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
After adjustment for baseline covariates, semaglutide was associated with greater weight reduction and LDL cholesterol improvement, whereas HbA1c reduction was comparable between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Summary · context
All patients received concurrent hypocaloric dietary intervention (1,200–1,400 kcal/day).
Report a problemFND-4183243710
05HumanObservational studyEfficacy outcome
In adults with newly diagnosed diabetes, dulaglutide was linked to less adjusted LDL cholesterol improvement than semaglutide.
In plain wordsIn adults with new diabetes, dulaglutide was linked to less improvement in LDL cholesterol than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedLDL cholesterol improvement
Study
n = 106
Comparator
Semaglutide 1.0 mg
Outcome group
Lipids · Metabolic and weight
Studied dose
1.5 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
After adjustment for baseline covariates, semaglutide was associated with greater weight reduction and LDL cholesterol improvement, whereas HbA1c reduction was comparable between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Summary · context
All patients received concurrent hypocaloric dietary intervention (1,200–1,400 kcal/day).
Report a problemFND-4183243711
06HumanObservational studyEfficacy outcome
In adults with newly diagnosed diabetes, adjusted HbA1c reduction was comparable with dulaglutide and semaglutide.
In plain wordsIn adults with new diabetes, dulaglutide and semaglutide were linked to similar blood sugar reductions.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeHbA1c reduction
Study
n = 106
Comparator
Semaglutide 1.0 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
After adjustment for baseline covariates, semaglutide was associated with greater weight reduction and LDL cholesterol improvement, whereas HbA1c reduction was comparable between groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Summary · context
All patients received concurrent hypocaloric dietary intervention (1,200–1,400 kcal/day).
Report a problemFND-4183243712
07HumanObservational studySafety outcome
In adults with newly diagnosed diabetes, pancreatic enzyme elevations were higher with dulaglutide than semaglutide.
In plain wordsIn adults with new diabetes, dulaglutide was linked to larger pancreatic enzyme increases than semaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreasePancreatic enzyme elevation
Study
n = 106
Comparator
Semaglutide 1.0 mg
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.5 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Mild increases in pancreatic enzyme levels were observed in both groups, with higher elevations in the dulaglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Summary · context
All patients received concurrent hypocaloric dietary intervention (1,200–1,400 kcal/day).
Report a problemFND-4183243713
08HumanObservational studyEfficacy outcome
In adults with newly diagnosed type 2 diabetes on a hypocaloric diet, semaglutide 1.0 mg significantly reduced HbA1c at 6 months.
In plain wordsIn adults with new type 2 diabetes on a low-calorie diet, long-term blood sugar fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c reduction at 6 months
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Both treatment groups demonstrated significant reductions in HbA1c, fasting blood glucose, liver enzymes, and lipid parameters at 6 months.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243701
09HumanObservational studyEfficacy outcome
In adults with newly diagnosed type 2 diabetes on a hypocaloric diet, semaglutide 1.0 mg significantly reduced fasting blood glucose at 6 months.
In plain wordsIn adults with new type 2 diabetes on a low-calorie diet, fasting blood sugar fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseFasting blood glucose reduction at 6 months
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Both treatment groups demonstrated significant reductions in HbA1c, fasting blood glucose, liver enzymes, and lipid parameters at 6 months.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243702
10HumanObservational studyEfficacy outcome
In adults with newly diagnosed type 2 diabetes on a hypocaloric diet, semaglutide 1.0 mg significantly reduced liver enzymes at 6 months.
In plain wordsIn adults with new type 2 diabetes on a low-calorie diet, liver enzyme levels fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLiver enzymes reduction at 6 months
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Both treatment groups demonstrated significant reductions in HbA1c, fasting blood glucose, liver enzymes, and lipid parameters at 6 months.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243703
11HumanObservational studyEfficacy outcome
In adults with newly diagnosed type 2 diabetes on a hypocaloric diet, semaglutide 1.0 mg significantly reduced lipid parameters at 6 months.
In plain wordsIn adults with new type 2 diabetes on a low-calorie diet, blood fat levels fell after 6 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseLipid parameters reduction at 6 months
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Both treatment groups demonstrated significant reductions in HbA1c, fasting blood glucose, liver enzymes, and lipid parameters at 6 months.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243704
12HumanObservational studySafety outcome
In adults with newly diagnosed type 2 diabetes, mild increases in pancreatic enzyme levels occurred with semaglutide, with higher elevations in the dulaglutide group.
In plain wordsIn adults with new type 2 diabetes, pancreas enzyme levels rose mildly in both groups, with higher rises on dulaglutide than on semaglutide.
Peptide
Semaglutide
Outcome
IncreasePancreatic enzyme elevation
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Mild increases in pancreatic enzyme levels were observed in both groups, with higher elevations in the dulaglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243708
13HumanObservational studySafety outcome
In adults with newly diagnosed type 2 diabetes, gastrointestinal adverse events were common but generally mild.
In plain wordsIn adults with new type 2 diabetes, stomach and gut side effects were common but mostly mild.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.0 mg · 6 monthsAs given in this study (human).
Source sentences
Summary
Gastrointestinal adverse events were common but generally mild.
1 context sentence(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Report a problemFND-4183243709

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

14HumanNot a test of Dulaglutide (Trulicity) aloneObservational studySafety outcome
In adults with newly diagnosed diabetes receiving dulaglutide or semaglutide, gastrointestinal adverse events were common but generally mild.
In plain wordsIn adults with new diabetes receiving dulaglutide or semaglutide, digestive side effects were common but generally mild.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableGastrointestinal adverse events
Study
n = 106
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Gastrointestinal adverse events were common but generally mild.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Summary · context
All patients received concurrent hypocaloric dietary intervention (1,200–1,400 kcal/day).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4183243714
15HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyEfficacy outcome
In adults with newly diagnosed diabetes, both dulaglutide and semaglutide groups showed significant reductions in glycemic measures, liver enzymes and lipid parameters.
In plain wordsIn adults with new diabetes, both drug groups had lower blood sugar, liver enzymes and lipid measures than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseCombined glycemic, liver enzyme and lipid changes
Study
n = 106
Comparator
Baseline in both treatment groups
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Source sentences
Summary
Both treatment groups demonstrated significant reductions in HbA1c, fasting blood glucose, liver enzymes, and lipid parameters at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective real-world study evaluated 106 adults aged 18–75 years with newly diagnosed T2D who initiated semaglutide (1.0 mg) or dulaglutide (1.5 mg) between December 2023 and December 2024.
Summary · context
All patients received concurrent hypocaloric dietary intervention (1,200–1,400 kcal/day).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4183243715

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.